Search This Blog

Thursday, August 6, 2020

Exelixis EPS beats by $0.11, beats on revenue

Exelixis (NASDAQ:EXEL): Q2 Non-GAAP EPS of $0.25 beats by $0.11; GAAP EPS of $0.21 beats by $0.09.
Revenue of $259.5M (+8.0% Y/Y) beats by $33.1M.
Net product sales (Cabozantinib Franchise Revenue) of $178.7M vs. consensus of $191.9M.
Press Release


Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)